Early-career scientists chosen for 2023 class of the Pew-Stewart Scholars Program for Cancer Research

The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust announced today the 2023 class of the Pew-Stewart Scholars Program for Cancer Research.

These early-career scientists will receive four-year grants to explore recent horizons in cancer development, diagnosis, and treatment. This class marks the tenth yr the Alexander and Margaret Stewart Trust has partnered with Pew to construct a legacy of modern cancer research.

Cancer is probably the most pressing challenges facing biomedical researchers today. Pew is proud to support such a promising cohort of scientists, and we sit up for seeing where their research pursuits lead.”

Susan K. Urahn, Pew’s President and CEO

Members of the 2023 class will explore critical issues in cancer research, including studying the event of pediatric cancers, discovering recent avenues for treating epithelial ovarian cancer, and pioneering chemistry to make cancer therapies more exact and effective.

“This yr marks a vital milestone as we have fun the tenth class of Pew-Stewart scholars,” said Peter Howley, M.D., chair of the Pew-Stewart national advisory committee. “I’m pleased to welcome such an exceptional group of scientists into our community, whose research will inform recent discoveries in our quest to higher understand and treat cancer.”

The 2023 Pew-Stewart Scholars for Cancer Research are:

Liron Bar-Peled, Ph.D.

Massachusetts General Hospital

Dr. Bar-Peled will improve how proteins are targeted in treating epithelial ovarian cancer.

Luisa Escobar-Hoyos, M.Sc., Ph.D.

Yale University

Dr. Escobar-Hoyos will explore the molecular processes that cause patients to change into immune to cancer immunotherapies.

Gerta Hoxhaj, Ph.D.

University of Texas Southwestern Medical Center

Dr. Hoxhaj will explore a link between cellular metabolism and metastatic disease.

Elvin Wagenblast, Ph.D.

Icahn School of Medicine at Mount Sinai

Dr. Wagenblast will investigate why specific cancer-driving mutations occur in pediatric leukemia prior to birth in comparison with different mutations seen in adult leukemia.

Ziyang Zhang, Ph.D.

University of California, Berkeley

Dr. Zhang will produce recent chemical tools that help develop simpler and fewer toxic therapies targeting difficult-to-treat cancer mutations.

Celebrating its seventy fifth anniversary, The Pew Charitable Trusts uses data to make a difference. Pew addresses the challenges of a changing world by illuminating issues, creating common ground, and advancing ambitious projects that result in tangible progress.